Stryker continues to outpace medtech peers with organic growth above 8% driven by Mako robotic surgery platform installed base expansion and procedure recovery from COVID backlog. Orthopaedic procedure volume durable as aging demographics offset GLP-1 surgical deferral concerns. Acquisition-led growth strategy proven. Neurovascular and endoscopy diversification adds resilience. Operating margin expansion path supports earnings growth above revenue growth.
Thesis reviewed May 29, 2026
Stryker Corporation is headquartered in United States, which is currently showing elevated risk signals.
πΊπΈUnited States78REDUCEView United States risk detail βπ₯Healthcare27NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| SYK | Stryker Corporation | 32 | +15% | β3% | EARLY |
| HCA | HCA Healthcare Inc. | 32 | +9% | β3% | EARLY |
| TEVA | Teva Pharmaceutical Industries Ltd. | 32 | +9% | β3% | NEUTRAL |
| TMO | Thermo Fisher Scientific Inc. | 32 | +11% | β3% | EARLY |
| CI | The Cigna Group | 32 | +9% | β3% | NEUTRAL |
| ELV | Elevance Health Inc. | 32 | +7% | β3% | NEUTRAL |
| DHR | Danaher Corporation | 32 | +11% | β3% | EARLY |
Investors who hold SYK may also have indirect exposure through these country funds.
Stryker Mako installed base exceeds 2,000 robots globally
Stryker organic growth +9%, exceeds large-cap medtech peers
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Thomas H. KeanNJ | R | Sell | Unknown amount | Jan 23, 26 | -17.9% |
| Julia LetlowLA | R | Buy | $1kβ$15k | Oct 16, 25 | -14.0% |
| Julia LetlowLA | R | Buy | $1kβ$15k | Oct 23, 24 | -14.0% |
| Gilbert CisnerosCA | D | Buy | $1kβ$15k | Dec 10, 25 | -15.3% |